(Q46504854)

22 December 2017

title

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers (English)

1 reference

22 December 2017

author

Pedro Dorado

4

1 reference

22 December 2017

author name string

Idilio González

1

1 reference

22 December 2017

Eva M Peñas-Lledó

2

1 reference

22 December 2017

Bárbaro Pérez

3

1 reference

22 December 2017

Mayra Alvarez

5

1 reference

22 December 2017

Adrián LLerena

6

1 reference

22 December 2017

Adrián LLerena

7

1 reference

22 December 2017

publication date

1 July 2008

1 reference

22 December 2017

published in

Pharmacogenomics

1 reference

22 December 2017

volume

9

1 reference

22 December 2017

issue

7

1 reference

22 December 2017

page(s)

833-840

1 reference

22 December 2017

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Relationship between Type A and B personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Association between cytochrome P450 2D6 genotype and harm avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Cytochrome P450 2D6 polymorphism and character traits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

No association between CYP2D6 polymorphisms and personality trait in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

The healthy control subject in psychiatric research: impulsiveness and volunteer bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Who are the people reluctant to participate in research? Personality correlates of four different types of nonresponse as inferred from self- and observer ratings

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Effect of personality type on pharmacodynamics through changing pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Tackling ethical dilemmas in personality assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

DEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Relationship between personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Estudio farmacogenético del polimorfismo metabólico de la debrisoquina (CYP2D6) en la población cubana en relación con la española

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

The Underlying Traits of the Karolinska Scales of Personality (KSP)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.833

21 January 2018

Identifiers

DOI

10.2217/14622416.9.7.833

1 reference

22 December 2017

PubMed ID

18597648

1 reference

22 December 2017